Effect of doxapram combined with nasal high-flow oxygen therapy in the treatment of chronic obstructive pulmonary disease(COPD)complicated with mild hypercapnia
Objective To investigate the effect of doxapram combined with nasal high flow oxygen therapy in the treatment of chronic obstructive pulmonary disease(COPD)with mild hypercapnia.Methods 96 patients with COPD complicated with mild hypercapnia admitted to the hospital from January 2023 to July 2023 were selected as the study objects.All of the patients were divided into control group and study group by random number table method,48 cases in each group.Both groups were given basic treatment,the control group was given high-flow nasal cannula oxygen therapy,and the study group was given doxapram combined with high-flow nasal cannula oxygen therapy.Pulmonary function,blood gas index and clinical efficacy were compared between the 2 groups.The levels of pulmonary surfactant protein(SP-D),Clara cell secretory protein(CC16)and Bathel index(BI)score were compared between the 2 groups.The inci-dence of adverse reactions was compared between the 2 groups.Results After the treatment,the forced expiratory volume in 1 second(FEV1)[(1.28±0.25)L vs(1.12±0.21)L],forced vital capacity(FVC)[(2.28±0.3)L vs(2.07±0.35)L]and FEV1/FVC[(56.14±5.12)％vs(54.11±4.78)％]in the study group were higher than those in the control group(P＜0.05).After the treatment,the arterial partial pressure of oxygen(PaO2)[(67.21±8.16)mmHg vs(58.43±7.65)mmHg]and blood oxygen satura-tion(SpO2)[(90.62±8.65)％vs(86.74±7.92)％]in the study group were higher than those in the con-trol group(P＜0.05),and the arterial partial pressure of carbon dioxide(PaCO2)[(40.53±2.70)mm-Hg vs(42.85±2.86)mmHg]was lower than those in the control group(P＜0.05).The total effective rate of the study group(93.75％vs 79.17％)was higher than that of the control group(x2=4.360,P=0.037).After the treatment,there were no statistically significant differences in SP-D levels[(38.12±9.53)mg/mL vs(40.18±9.85)mg/mL]and CC16 levels[(86.14±9.25)ng/mLvs(84.33±9.07)ng/mL]between the 2 groups(t=1.095,0.968,P=0.276,0.336).After the treatment,the BI score of the stud-y group[(73.88±6.16)vs(71.23±5.94)]was higher than that of the control group(t=2.145,P=0.034).The total incidence of adverse reactions in the 2 groups(14.58％vs 10.42％)was similar(x2=0.381,P=0.537).Conclusion The combination of doxapram and nasal high flow oxygen therapy in the treatment of COPD with mild hypercapnia can improve lung function,improve blood gas indicators,clini-cal efficacy,and quality of life in patients,and it is safe and reliable.
chronic obstructive pulmonary disease(COPD)mild hypercapniadoshaplentransnasal high flow oxygen therapyclinical efficacylung function
NETL
NSTL
万方数据
